U.S. markets open in 6 hours 42 minutes

Emergent BioSolutions Inc. (EBS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
92.31+1.44 (+1.58%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close90.87
Bid0.00 x 800
Ask0.00 x 1000
Day's Range86.16 - 92.99
52 Week Range46.37 - 137.61
Avg. Volume602,405
Market Cap4.92B
Beta (5Y Monthly)1.18
PE Ratio (TTM)16.28
EPS (TTM)5.67
Earnings DateApr 28, 2021 - May 03, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est118.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
80% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Yahoo Finance Video

    Emergent Biosolutions CEO on JNJ vaccine production

    Robert Kramer, Emergent Biosolutions CEO, joins the Yahoo Finance Live panel to discuss his outlook on COVID-19 as the company manufactures the Johnson & Johnson one-shot vaccine. 

  • Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says

    Emergent BioSolutions Capable Of Manufacturing 1B COVID-19 Vaccine Doses Annually, CEO Says

    Emergent BioSolutions Inc (NYSE: EBS) has built the capacity to produce vaccines from AstraZeneca Plc (NASDAQ: AZN) and Johnson & Johnson (NYSE: JNJ) around the clock, said CEO Bob Kramer on CNBC. “We are operating at a level where our capacity is well in excess of 1 billion doses annually for those products.” said the CEO. The company bagged a five-year deal with JNJ to produce its COVID-19 vaccine, valued at about $480 million for the first two years. It also entered into a multi-year contract production pact for AstraZeneca’s COVID-19 vaccine. The three-year contract is valued at $174 million through 2021. AZN contract is in addition to an million deal that was announced to secure production space. The J&J vaccine is being produced at Emergent BioSolutions’ Baltimore Bayview facility, one of three Centers for Innovation in Advanced Development and Manufacturing designated by the U.S. government as a rapid vaccine therapeutics manufacturing site. In addition to Emergent BioSolutions, the White House earlier this week arranged a deal with Merck & Co Inc (NYSE: MRK) to help boost J&J’s one-dose vaccine production. President Joe Biden said that he expects the U.S. to have a vaccine supply of 300 million within the next few months, which he says is substantial enough to reach all adults. The projected timeline for building up this supply was also moved to May from the end of July. J&J expects to deliver 20 million shots in the U.S. this month, while a total of 100 million doses are planned for the first half of this year. Price Action: EBS shares closed 4.6% lower at $94.73 on Wednesday. See more from BenzingaClick here for options trades from BenzingaOcugen Shares Are Trading Higher On Its Partner's COVID-19 Vaccine Candidate Showing 81% EfficacyEU Considers Emergency Approvals To Boost COVID-19 Vaccine Rollout: Reuters© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.